Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Time to Buy?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up prior to trading on Monday . The stock had previously closed at $45.02, but opened at $47.50. Zealand Pharma A/S shares last traded at $47.50, with a volume of 212 shares traded.

Analysts Set New Price Targets

ZLDPF has been the subject of several research analyst reports. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The firm has a market capitalization of $3.40 billion, a P/E ratio of 3.52 and a beta of 0.88. The firm has a 50 day moving average price of $45.58 and a 200-day moving average price of $50.45. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.50. The firm had revenue of $5.33 million for the quarter, compared to the consensus estimate of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. On average, analysts expect that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.